Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma (Journal article)

Froudarakis, M. E./ Pataka, A./ Pappas, P./ Anevlavis, S./ Argiana, E./ Nikolaidou, M./ Kouliatis, G./ Pozova, S./ Marselos, M./ Bouros, D.


BACKGROUND: : Lipoplatin is a new liposomal cisplatin that already has been tested in solid tumors, with encouraging results. The purpose of the current study was to determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of a 21-day regimen of lipoplatin plus a fixed dose of gemcitabine in patients with refractory or resistant nonsmall cell lung carcinoma (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status of
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Aged,Aged, 80 and over,Antineoplastic Combined Chemotherapy Protocols/*pharmacokinetics/*therapeutic use,Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality,Cisplatin/administration & dosage/adverse effects/pharmacokinetics,Deoxycytidine/administration & dosage/adverse effects/analogs &,derivatives/pharmacokinetics,Female,Humans,Kaplan-Meier Estimate,Lung Neoplasms/*drug therapy/mortality,Male,Maximum Tolerated Dose,Middle Aged,Salvage Therapy/adverse effects
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/19331
ISSN: 0008-543X
Link: http://www.ncbi.nlm.nih.gov/pubmed/18823054
http://onlinelibrary.wiley.com/store/10.1002/cncr.23921/asset/23921_ftp.pdf?v=1&t=h0dexb8u&s=56616e5d680419c1c6fa4918167a9dad39ba04d6
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Froudarakis-2008-Phase 1 trial of lip.pdf146.96 kBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/19331
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.